Epigenetic regulation of drug transporter expression in human tissues

References

• Sissung TM, Troutman SM, Campbell TJ, et al. Transporter pharmacogenetics: transporter polymorphisms affect normal physiology, diseases, and pharmacotherapy. Discov Med. 2012;13:19–34.
   PubMed Web of Science ®Google Scholar
• Bonder MJ, Kasela S, Kals M, et al. Genetic and epigenetic regulation of gene expression in fetal and adult human livers. BMC Genomics. 2014;15:860.
   PubMed Web of Science ®Google Scholar
• Ivanov M, Kacevska M, Ingelman-Sundberg M. Epigenomics and interindividual differences in drug response. Clin Pharmacol Ther. 2012;92:727–736.
   PubMed Web of Science ®Google Scholar
• Ingelman-Sundberg M, Sim SC, Gomez A, et al. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther. 2007;116:496–526.
   PubMed Web of Science ®Google Scholar
• Wagner PD, Verma M, Srivastava S. Challenges for biomarkers in cancer detection. Ann NY Acad Sci. 2004;1022:9–16.
   PubMed Web of Science ®Google Scholar
• Robertson KD. DNA methylation and human disease. Nat Rev Genet. 2005;6:597–610.
   PubMed Web of Science ®Google Scholar
• Wilson AS, Power BE, Molloy PL. DNA hypomethylation and human diseases. Biochim Biophys Acta. 2007;1775:138–162.
   PubMed Web of Science ®Google Scholar
• Wu L-XX, Wen C-JJ, Li Y, et al. Interindividual epigenetic variation in ABCB1 promoter and its relationship with ABCB1 expression and function in healthy Chinese subjects. Br J Clin Pharmacol. 2015;80:1109–1121.
   PubMed Web of Science ®Google Scholar
• Efferth T, Futscher BW, Osieka R. 5-Azacytidine modulates the response of sensitive and multidrug-resistant K562 leukemic cells to cytostatic drugs. Blood Cells Mol Dis. 2001;27:637–648.
   PubMed Web of Science ®Google Scholar
• David GL, Yegnasubramanian S, Kumar A, et al. MDR1 promoter hypermethylation in MCF-7 human breast cancer cells: changes in chromatin structure induced by treatment with 5-Aza-cytidine. Cancer Biol Ther. 2004;3:540–548.
   PubMed Web of Science ®Google Scholar
• Takeda M, Mizokami A, Mamiya K, et al. The establishment of two paclitaxel-resistant prostate cancer cell lines and the mechanisms of paclitaxel resistance with two cell lines. Prostate. 2007;67:955–967.
   PubMed Web of Science ®Google Scholar
• Marguerite V, Beri-Dexheimer M, Ortiou S, et al. Cobalamin potentiates vinblastine cytotoxicity through downregulation of mdr-1 gene expression in HepG2 cells. Cell Physiol Biochem. 2007;20:967–761.
   PubMed Web of Science ®Google Scholar
• Reed K, Hembruff SL, Laberge ML, et al. Hypermethylation of the ABCB1 downstream gene promoter accompanies ABCB1 gene amplification and increased expression in docetaxel-resistant MCF-7 breast tumor cells. Epigenetics. 2008;3:270–280.
   PubMed Web of Science ®Google Scholar
• Reed K, Hembruff SL, Sprowl JA, et al. The temporal relationship between ABCB1 promoter hypomethylation, ABCB1 expression and acquisition of drug resistance. Pharmacogenomics J. 2010;10:489–504.
   PubMed Web of Science ®Google Scholar
• Shi C-JJ, Wang F, Ren M-FF, et al. Up-regulation of ABCB1/P-glycoprotein by escaping promoter hypermethylation indicates poor prognosis in hematologic malignancy patients with and without bone marrow transplantation. Leuk Res. 2011;35:73–79.
   PubMed Web of Science ®Google Scholar
• To KK, Zhan Z, Bates SE. Aberrant promoter methylation of the ABCG2 gene in renal carcinoma. Mol Cell Biol. 2006;26:8572–8585.
   PubMed Web of Science ®Google Scholar
• Turner JG, Gump JL, Zhang C, et al. ABCG2 expression, function, and promoter methylation in human multiple myeloma. Blood. 2006;108:3881–3889.
   PubMed Web of Science ®Google Scholar
• Nakano H, Nakamura Y, Soda H, et al. Methylation status of breast cancer resistance protein detected by methylation-specific polymerase chain reaction analysis is correlated inversely with its expression in drug-resistant lung cancer cells. Cancer. 2008;112:1122–1130.
   PubMed Web of Science ®Google Scholar
• Nakamichi N, Morii E, Ikeda J, et al. Synergistic effect of interleukin-6 and endoplasmic reticulum stress inducers on the high level of ABCG2 expression in plasma cells. Lab Invest. 2009;89:327–336.
   PubMed Web of Science ®Google Scholar
• Bram EE, Stark M, Raz S, et al. Chemotherapeutic drug-induced ABCG2 promoter demethylation as a novel mechanism of acquired multidrug resistance. Neoplasia. 2009;11:1359–1370.
   PubMed Web of Science ®Google Scholar
• Porro A, Iraci N, Soverini S, et al. c-MYC oncoprotein dictates transcriptional profiles of ATP-binding cassette transporter genes in chronic myelogenous leukemia CD34+ hematopoietic progenitor cells. Mol Cancer Res. 2011;9:1054–1066.
   PubMed Web of Science ®Google Scholar
• Schaeffeler E, Hellerbrand C, Nies AT, et al. DNA methylation is associated with downregulation of the organic cation transporter OCT1 (SLC22A1) in human hepatocellular carcinoma. Genome Med. 2011;3:82.
   PubMed Web of Science ®Google Scholar
• Lin R, Li X, Li J, et al. Long-term cisplatin exposure promotes methylation of the OCT1 gene in human esophageal cancer cells. Dig Dis Sci. 2013;58:694–698.
   PubMed Web of Science ®Google Scholar
• Aoki M, Terada T, Kajiwara M, et al. Kidney-specific expression of human organic cation transporter 2 (OCT2/SLC22A2) is regulated by DNA methylation. Am J Physiol Renal Physiol. 2008;295:F165–F170.
   PubMed Web of Science ®Google Scholar
• Ikehata M, Ueda K, Iwakawa S. Different involvement of DNA methylation and histone deacetylation in the expression of solute-carrier transporters in 4 colon cancer cell lines. Biol Pharm Bull. 2012;35:301–307.
   PubMed Web of Science ®Google Scholar
• Chen L, Hong C, Chen EC, et al. Genetic and epigenetic regulation of the organic cation transporter 3, SLC22A3. Pharmacogenomics J. 2013;13:110–120.
   PubMed Web of Science ®Google Scholar
• Qu Q, Qu J, Zhan M, et al. Different involvement of promoter methylation in the expression of organic cation/carnitine transporter 2 (OCTN2) in cancer cell lines. PLoS ONE. 2013;8:e76474.
   PubMed Web of Science ®Google Scholar
• Jin L, Kikuchi R, Saji T, et al. Regulation of tissue-specific expression of renal organic anion transporters by hepatocyte nuclear factor 1 α/β and DNA methylation. J Pharmacol Exp Ther. 2012;340:648–655.
   PubMed Web of Science ®Google Scholar
• Kikuchi R, Kusuhara H, Hattori N, et al. Regulation of the expression of human organic anion transporter 3 by hepatocyte nuclear factor 1alpha/beta and DNA methylation. Mol Pharmacol. 2006;70:887–896.
   PubMed Web of Science ®Google Scholar
• Imai S, Kikuchi R, Kusuhara H, et al. DNA methylation and histone modification profiles of mouse organic anion transporting polypeptides. Drug Metab Dispos. 2013;41:72–78.
   PubMed Web of Science ®Google Scholar
• Imai S, Kikuchi R, Tsuruya Y, et al. Epigenetic regulation of organic anion transporting polypeptide 1B3 in cancer cell lines. Pharm Res. 2013;30:2880–2890.
   PubMed Web of Science ®Google Scholar
• Kim RB. Drugs as P-glycoprotein substrates, inhibitors, and inducers. Drug Metab Rev. 2002;34:47–54.
   PubMed Web of Science ®Google Scholar
• Sharom FJ. The P-glycoprotein multidrug transporter. Essays Biochem. 2011;50:161–178.
   PubMed Web of Science ®Google Scholar
• Ueda K, Clark DP, Chen CJ, et al. The human multidrug resistance (mdr1) gene. cDNA cloning and transcription initiation. J Biol Chem. 1987;262:505–508.
   PubMed Web of Science ®Google Scholar
• Huff LM, Wang Z, Iglesias A, et al. Aberrant transcription from an unrelated promoter can result in MDR-1 expression following drug selection in vitro and in relapsed lymphoma samples. Cancer Res. 2005;65:11694–11703.
   PubMed Web of Science ®Google Scholar
• Raguz S, Randle RA, Sharpe ER, et al. Production of P-glycoprotein from the MDR1 upstream promoter is insufficient to affect the response to first-line chemotherapy in advanced breast cancer. Int J Cancer. 2008;122:1058–1067.
   PubMed Web of Science ®Google Scholar
• Mealey KL. ABCG2 transporter: therapeutic and physiologic implications in veterinary species. J Vet Pharmacol Ther. 2012;35:105–112.
   PubMed Web of Science ®Google Scholar
• Hilgendorf C, Ahlin G, Seithel A, et al. Expression of thirty-six drug transporter genes in human intestine, liver, kidney, and organotypic cell lines. Drug Metab Dispos. 2007;35:1333–1340.
   PubMed Web of Science ®Google Scholar
• Kunze A, Huwyler J, Camenisch G, et al. Prediction of organic anion-transporting polypeptide 1B1- and 1B3-mediated hepatic uptake of statins based on transporter protein expression and activity data. Drug Metab Dispos. 2014;42:1514–1521.
   PubMed Web of Science ®Google Scholar
• Treiber A, Schneiter R, Häusler S, et al. Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil. Drug Metab Dispos. 2007;35:1400–1407.
   PubMed Web of Science ®Google Scholar
• Sato T, Yamaguchi H, Kogawa T, et al. Organic anion transporting polypeptides 1B1 and 1B3 play an important role in uremic toxin handling and drug-uremic toxin interactions in the liver. J Pharm Pharm Sci. 2014;17:475–484.
   PubMed Web of Science ®Google Scholar
• Nagai M, Furihata T, Matsumoto S, et al. Identification of a new organic anion transporting polypeptide 1B3 mRNA isoform primarily expressed in human cancerous tissues and cells. Biochem Biophys Res Commun. 2012;418:818–823.
   PubMed Web of Science ®Google Scholar
• Feng Q, Zhang Y. The MeCP1 complex represses transcription through preferential binding, remodeling, and deacetylating methylated nucleosomes. Genes Dev. 2001;15:827–832.
   PubMed Web of Science ®Google Scholar
• Ye J, Liu Q, Wang C, et al. Inhibitory effect of JBP485 on renal excretion of acyclovir by the inhibition of OAT1 and OAT3. Eur J Pharm Sci. 2012;47:341–346.
   PubMed Web of Science ®Google Scholar
• Ueo H, Motohashi H, Katsura T, et al. Human organic anion transporter hOAT3 is a potent transporter of cephalosporin antibiotics, in comparison with hOAT1. Biochem Pharmacol. 2005;70:1104–1113.
   PubMed Web of Science ®Google Scholar
• Tahara H, Kusuhara H, Endou H, et al. A species difference in the transport activities of H2 receptor antagonists by rat and human renal organic anion and cation transporters. J Pharmacol Exp Ther. 2005;315:337–345.
   PubMed Web of Science ®Google Scholar
• More SS, Li S, Yee SW, et al. Organic cation transporters modulate the uptake and cytotoxicity of picoplatin, a third-generation platinum analogue. Mol Cancer Ther. 2010;9:1058–1069.
   PubMed Web of Science ®Google Scholar
• Nies AT, Koepsell H, Winter S, et al. Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver. Hepatology. 2009;50:1227–1240.
   PubMed Web of Science ®Google Scholar
• Kimura N, Okuda M, Inui K. Metformin transport by renal basolateral organic cation transporter hOCT2. Pharm Res. 2005;22:255–259.
   PubMed Web of Science ®Google Scholar
• Backs J, Olson EN. Control of cardiac growth by histone acetylation/deacetylation. Circ Res. 2006;98:15–24.
   PubMed Web of Science ®Google Scholar
• Lobera M, Madauss KP, Pohlhaus DT, et al. Selective class IIa histone deacetylase inhibition via a nonchelating zinc-binding group. Nat Chem Biol. 2013;9:319–325.
   PubMed Web of Science ®Google Scholar
• Xiao JJ, Huang Y, Dai Z, et al. Chemoresistance to depsipeptide FK228 [(E)-(1S,4S,10S,21R)-7-[(Z)-ethylidene]-4,21-diisopropyl-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8,7,6]-tricos-16-ene-3,6,9,22-pentanone] is mediated by reversible MDR1 induction in human cancer cell lines. J Pharmacol Exp Ther. 2005;314:467–475.
   PubMed Web of Science ®Google Scholar
• Baker EK, Johnstone RW, Zalcberg JR, et al. Epigenetic changes to the MDR1 locus in response to chemotherapeutic drugs. Oncogene. 2005;24:8061–8075.
   PubMed Web of Science ®Google Scholar
• Chen KG, Wang YC, Schaner ME, et al. Genetic and epigenetic modeling of the origins of multidrug-resistant cells in a human sarcoma cell line. Cancer Res. 2005;65:9388–9397.
   PubMed Web of Science ®Google Scholar
• Yatouji S, El-Khoury V, Trentesaux C, et al. Differential modulation of nuclear texture, histone acetylation, and MDR1 gene expression in human drug-sensitive and -resistant OV1 cell lines. Int J Oncol. 2007;30:1003–1009.
   PubMed Web of Science ®Google Scholar
• El-Khoury V, Breuzard G, Fourré N, et al. The histone deacetylase inhibitor trichostatin A downregulates human MDR1 (ABCB1) gene expression by a transcription-dependent mechanism in a drug-resistant small cell lung carcinoma cell line model. Br J Cancer. 2007;97:562–573.
   PubMed Web of Science ®Google Scholar
• Hirota T, Takane H, Higuchi S, et al. Epigenetic regulation of genes encoding drug-metabolizing enzymes and transporters; DNA methylation and other mechanisms. Curr Drug Metab. 2008;9:34–38.
   PubMed Web of Science ®Google Scholar
• Lee T-B-B, Park J-H-H, Min Y-D-D, et al. Epigenetic mechanisms involved in differential MDR1 mRNA expression between gastric and colon cancer cell lines and rationales for clinical chemotherapy. BMC Gastroenterol. 2008;8:33.
   PubMed Web of Science ®Google Scholar
• Kim S-NN, Kim NH, Lee W, et al. Histone deacetylase inhibitor induction of P-glycoprotein transcription requires both histone deacetylase 1 dissociation and recruitment of CAAT/enhancer binding protein beta and pCAF to the promoter region. Mol Cancer Res. 2009;7:735–744.
   PubMed Web of Science ®Google Scholar
• Hauswald S, Duque-Afonso J, Wagner MM, et al. Histone deacetylase inhibitors induce a very broad, pleiotropic anticancer drug resistance phenotype in acute myeloid leukemia cells by modulation of multiple ABC transporter genes. Clin Cancer Res. 2009;15:3705–3715.
   PubMed Web of Science ®Google Scholar
• Jin W, Liu Y, Xu SG, et al. UHRF1 inhibits MDR1 gene transcription and sensitizes breast cancer cells to anticancer drugs. Breast Cancer Res Treat. 2010;124:39–48.
   PubMed Web of Science ®Google Scholar
• Xu Y, Jiang Z, Yin P, et al. Role for class I histone deacetylases in multidrug resistance. Exp Cell Res. 2012;318:177–186.
   PubMed Web of Science ®Google Scholar
• Toth M, Boros IM, Balint E. Elevated level of lysine 9-acetylated histone H3 at the MDR1 promoter in multidrug-resistant cells. Cancer Sci. 2012;103:659–669.
   PubMed Web of Science ®Google Scholar
• Kim H, Kim S-NN, Park Y-SS, et al. HDAC inhibitors downregulate MRP2 expression in multidrug resistant cancer cells: implication for chemosensitization. Int J Oncol. 2011;38:807–127.
   PubMed Web of Science ®Google Scholar
• To KK, Polgar O, Huff LM, et al. Histone modifications at the ABCG2 promoter following treatment with histone deacetylase inhibitor mirror those in multidrug-resistant cells. Mol Cancer Res. 2008;6:151–164.
   PubMed Web of Science ®Google Scholar
• Zhou S-FF, Wang L-LL, Di YM, et al. Substrates and inhibitors of human multidrug resistance associated proteins and the implications in drug development. Curr Med Chem. 2008;15:1981–2039.
   PubMed Web of Science ®Google Scholar
• Huo H, Magro PG, Pietsch EC, et al. Histone methyltransferase MLL1 regulates MDR1 transcription and chemoresistance. Cancer Res. 2010;70:8726–8735.
   PubMed Web of Science ®Google Scholar
• Saito J, Hirota T, Kikunaga N, et al. Interindividual differences in placental expression of the SLC22A2 (OCT2) gene: relationship to epigenetic variations in the 5ʹ-upstream regulatory region. J Pharm Sci. 2011;100:3875–3883.
   PubMed Web of Science ®Google Scholar
• Sadakierska-Chudy A, Filip M. A comprehensive view of the epigenetic landscape. Part II: histone post-translational modification, nucleosome level, and chromatin regulation by ncRNAs. Neurotox Res. 2015;27:172–197.
   PubMed Web of Science ®Google Scholar
• Lv Y-CC, Tang Y-YY, Peng J, et al. MicroRNA-19b promotes macrophage cholesterol accumulation and aortic atherosclerosis by targeting ATP-binding cassette transporter A1. Atherosclerosis. 2014;236:215–226.
   PubMed Web of Science ®Google Scholar
• Goedeke L, Rotllan N, Ramírez CM, et al. miR-27b inhibits LDLR and ABCA1 expression but does not influence plasma and hepatic lipid levels in mice. Atherosclerosis. 2015;243:499–509.
   PubMed Web of Science ®Google Scholar
• Jan A, Karasinska JM, Kang MH, et al. Direct intracerebral delivery of a miR-33 antisense oligonucleotide into mouse brain increases brain ABCA1 expression. [Corrected]. Neurosci Lett. 2015;598:66–72.
   PubMed Web of Science ®Google Scholar
• Rayner KJ, Esau CC, Hussain FN, et al. Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides. Nature. 2011;478:404–407.
   PubMed Web of Science ®Google Scholar
• Zhang N, Lei J, Lei H, et al. MicroRNA-101 overexpression by IL-6 and TNF-α inhibits cholesterol efflux by suppressing ATP-binding cassette transporter A1 expression. Exp Cell Res. 2015;336:33–42.
   PubMed Web of Science ®Google Scholar
• De Aguiar Vallim TQ, Tarling EJ, Kim T, et al. MicroRNA-144 regulates hepatic ATP binding cassette transporter A1 and plasma high-density lipoprotein after activation of the nuclear receptor farnesoid X receptor. Circ Res. 2013;112:1602–1612.
   PubMed Web of Science ®Google Scholar
• Goedeke L, Rotllan N, Canfrán-Duque A, et al. MicroRNA-148a regulates LDL receptor and ABCA1 expression to control circulating lipoprotein levels. Nat Med. 2015;21:1280–1289.
   PubMed Web of Science ®Google Scholar
• Zhu H, Wu H, Liu X, et al. Role of microRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cells. Biochem Pharmacol. 2008;76:582–588.
   PubMed Web of Science ®Google Scholar
• Li Z, Hu S, Wang J, et al. MiR-27a modulates MDR1/P-glycoprotein expression by targeting HIPK2 in human ovarian cancer cells. Gynecol Oncol. 2010;119:125–130.
   PubMed Web of Science ®Google Scholar
• Feng -D-D-D, Zhang H, Zhang P, et al. Down-regulated miR-331-5p and miR-27a are associated with chemotherapy resistance and relapse in leukaemia. J Cell Mol Med. 2011;15:2164–2175.
   PubMed Web of Science ®Google Scholar
• Zhang H, Li M, Han Y, et al. Down-regulation of miR-27a might reverse multidrug resistance of esophageal squamous cell carcinoma. Dig Dis Sci. 2010;55:2545–2551.
   PubMed Web of Science ®Google Scholar
• Chen Z, Ma T, Huang C, et al. MiR-27a modulates the MDR1/P-glycoprotein expression by inhibiting FZD7/β-catenin pathway in hepatocellular carcinoma cells. Cell Signal. 2013;25:2693–2701.
   PubMed Web of Science ®Google Scholar
• Long Q-Z-Z, Du Y-F-F, Liu X-G-G, et al. miR-124 represses FZD5 to attenuate P-glycoprotein-mediated chemo-resistance in renal cell carcinoma. Tumour Biol. 2015;36:7017–7026.
   PubMed Web of Science ®Google Scholar
• Yang L, Li N, Wang H, et al. Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance. Oncol Rep. 2012;28:592–600.
   PubMed Web of Science ®Google Scholar
• Takwi AA, Wang Y-MM, Wu J, et al. miR-137 regulates the constitutive androstane receptor and modulates doxorubicin sensitivity in parental and doxorubicin-resistant neuroblastoma cells. Oncogene. 2014;33:3717–3729.
   PubMed Web of Science ®Google Scholar
• Zhao X, Yang L, Hu J, et al. miR-138 might reverse multidrug resistance of leukemia cells. Leuk Res. 2010;34:1078–1082.
   PubMed Web of Science ®Google Scholar
• Ikemura K, Yamamoto M, Miyazaki S, et al. MicroRNA-145 post-transcriptionally regulates the expression and function of P-glycoprotein in intestinal epithelial cells. Mol Pharmacol. 2013;83:399–405.
   PubMed Web of Science ®Google Scholar
• Chen J, Tian W, Cai H, et al. Down-regulation of microRNA-200c is associated with drug resistance in human breast cancer. Med Oncol. 2012;29:2527–2534.
   PubMed Web of Science ®Google Scholar
• Sui H, Cai GX, Pan SF, et al. miR200c attenuates P-gp-mediated MDR and metastasis by targeting JNK2/c-Jun signaling pathway in colorectal cancer. Mol Cancer Ther. 2014;13:3137–3151.
   PubMed Web of Science ®Google Scholar
• Yang T, Zheng Z-M-M, Li X-N-N, et al. MiR-223 modulates multidrug resistance via downregulation of ABCB1 in hepatocellular carcinoma cells. Exp Biol Med (Maywood). 2013;238:1024–1032.
   PubMed Web of Science ®Google Scholar
• Bao L, Hazari S, Mehra S, et al. Increased expression of P-glycoprotein and doxorubicin chemoresistance of metastatic breast cancer is regulated by miR-298. Am J Pathol. 2012;180:2490–2503.
   PubMed Web of Science ®Google Scholar
• Xu Y, Ohms SJ, Li Z, et al. Changes in the expression of miR-381 and miR-495 are inversely associated with the expression of the MDR1 gene and development of multi-drug resistance. PLoS ONE. 2013;8:e82062.
   PubMed Web of Science ®Google Scholar
• Kovalchuk O, Filkowski J, Meservy J, et al. Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. Mol Cancer Ther. 2008;7:2152–2159.
   PubMed Web of Science ®Google Scholar
• Shang Y, Zhang Z, Liu Z, et al. miR-508-5p regulates multidrug resistance of gastric cancer by targeting ABCB1 and ZNRD1. Oncogene. 2014;33:3267–3276.
   PubMed Web of Science ®Google Scholar
• Pogribny IP, Filkowski JN, Tryndyak VP, et al. Alterations of microRNAs and their targets are associated with acquired resistance of MCF-7 breast cancer cells to cisplatin. Int J Cancer. 2010;127:1785–1794.
   PubMed Web of Science ®Google Scholar
• Liu H, Wu X, Huang J, et al. miR-7 modulates chemoresistance of small cell lung cancer by repressing MRP1/ABCC1. Int J Exp Pathol. 2015;96:240–247.
   PubMed Web of Science ®Google Scholar
• Ma J, Wang T, Guo R, et al. Involvement of miR-133a and miR-326 in ADM resistance of HepG2 through modulating expression of ABCC1. J Drug Target. 2015;23:519–524.
   PubMed Web of Science ®Google Scholar
• Lu L, Ju F, Zhao H, et al. MicroRNA-134 modulates resistance to doxorubicin in human breast cancer cells by downregulating ABCC1. Biotechnol Lett. 2015;37:2387–2394.
   PubMed Web of Science ®Google Scholar
• Liang Z, Wu H, Xia J, et al. Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1. Biochem Pharmacol. 2010;79:817–824.
   PubMed Web of Science ®Google Scholar
• Pan Y-Z-Z, Zhou A, Hu Z, et al. Small nucleolar RNA-derived microRNA hsa-miR-1291 modulates cellular drug disposition through direct targeting of ABC transporter ABCC1. Drug Metab Dispos. 2013;41:1744–1751.
   PubMed Web of Science ®Google Scholar
• Xu K, Liang X, Shen K, et al. miR-297 modulates multidrug resistance in human colorectal carcinoma by down-regulating MRP-2. Biochem J. 2012;446:291–300.
   PubMed Web of Science ®Google Scholar
• Haenisch S, Laechelt S, Bruckmueller H, et al. Down-regulation of ATP-binding cassette C2 protein expression in HepG2 cells after rifampicin treatment is mediated by microRNA-379. Mol Pharmacol. 2011;80:314–320.
   PubMed Web of Science ®Google Scholar
• Shen W-WW, Zeng Z, Zhu W-XX, et al. MiR-142-3p functions as a tumor suppressor by targeting CD133, ABCG2, and Lgr5 in colon cancer cells. J Mol Med. 2013;91:989–10001.
   PubMed Web of Science ®Google Scholar
• Jiao X, Zhao L, Ma M, et al. MiR-181a enhances drug sensitivity in mitoxantone-resistant breast cancer cells by targeting breast cancer resistance protein (BCRP/ABCG2). Breast Cancer Res Treat. 2013;139:717–730.
   PubMed Web of Science ®Google Scholar
• Cheng W, Liu T, Wan X, et al. MicroRNA-199a targets CD44 to suppress the tumorigenicity and multidrug resistance of ovarian cancer-initiating cells. FEBS J. 2012;279:2047–2059.
   PubMed Web of Science ®Google Scholar
• Turrini E, Haenisch S, Laechelt S, et al. MicroRNA profiling in K-562 cells under imatinib treatment: influence of miR-212 and miR-328 on ABCG2 expression. Pharmacogenet Genomics. 2012;22:198–205.
   PubMed Web of Science ®Google Scholar
• Pan Y-ZZ, Morris ME, Yu A-MM. MicroRNA-328 negatively regulates the expression of breast cancer resistance protein (BCRP/ABCG2) in human cancer cells. Mol Pharmacol. 2009;75:1374–1379.
   PubMed Web of Science ®Google Scholar
• Li X, Pan YZ, Seigel GM, et al. Breast cancer resistance protein BCRP/ABCG2 regulatory microRNAs (hsa-miR-328, −519c and −520h) and their differential expression in stem-like ABCG2+ cancer cells. Biochem Pharmacol. 2011;81:783–792.
   PubMed Web of Science ®Google Scholar
• Ma M-TT, He M, Wang Y, et al. MiR-487a resensitizes mitoxantrone (MX)-resistant breast cancer cells (MCF-7/MX) to MX by targeting breast cancer resistance protein (BCRP/ABCG2). Cancer Lett. 2013;339:107–115.
   PubMed Web of Science ®Google Scholar
• To KK, Zhan Z, Litman T, et al. Regulation of ABCG2 expression at the 3ʹ untranslated region of its mRNA through modulation of transcript stability and protein translation by a putative microRNA in the S1 colon cancer cell line. Mol Cell Biol. 2008;28:5147–5161.
   PubMed Web of Science ®Google Scholar
• Padmanabhan R, Chen KG, Gillet J-P-P, et al. Regulation and expression of the ATP-binding cassette transporter ABCG2 in human embryonic stem cells. Stem Cells. 2012;30:2175–2187.
   PubMed Web of Science ®Google Scholar
• To KK, Leung WW, Ng SS. Exploiting a novel miR-519c-HuR-ABCG2 regulatory pathway to overcome chemoresistance in colorectal cancer. Exp Cell Res. 2015;338:222–231.
   PubMed Web of Science ®Google Scholar
• Oram JF, Lawn RM. ABCA1. The gatekeeper for eliminating excess tissue cholesterol. J Lipid Res. 2001;42:1173–1179.
   PubMed Web of Science ®Google Scholar
• Lv YC, Yin K, Fu YC, et al. Posttranscriptional regulation of ATP-binding cassette transporter A1 in lipid metabolism. DNA Cell Biol. 2013;32:348–358.
   PubMed Web of Science ®Google Scholar
• Oram JF, Heinecke JW. ATP-binding cassette transporter A1: a cell cholesterol exporter that protects against cardiovascular disease. Physiol Rev. 2005;85:1343–1372.
   PubMed Web of Science ®Google Scholar
• Rikke-Schmidt R, Nordestgaard BGG, Jensen GB, et al. Genetic variation in ABC transporter A1 contributes to HDL cholesterol in the general population. J Clin Invest. 2004;114:1343–1353.
   PubMed Web of Science ®Google Scholar
• Wang D, Sadée W. Searching for polymorphisms that affect gene expression and mRNA processing: example ABCB1 (MDR1). Aaps J. 2006;8:E515–201.
   PubMed Web of Science ®Google Scholar
• Kimchi-Sarfaty C, Oh JM, Kim I-W-W, et al. A “silent” polymorphism in the MDR1 gene changes substrate specificity. Science. 2007;315:525–528.
   PubMed Web of Science ®Google Scholar
• Bruhn O, Drerup K, Kaehler M, et al. Length variants of the ABCB1 3′-UTR and loss of miRNA binding sites: possible consequences in regulation and pharmacotherapy resistance. Pharmacogenomics. 2016;17:327–340.
   PubMed Web of Science ®Google Scholar
• Liu H, Wu X, Huang J, et al. miR-7 modulates chemoresistance of small cell lung cancer by repressing MRP1/ABCC1. Int J Exp Pathol. 2015;96:240–247.
   PubMed Web of Science ®Google Scholar
• Ripperger A, Benndorf RA. The C421A (Q141K) polymorphism enhances the 3ʹ-untranslated region (3ʹ-UTR)-dependent regulation of ATP-binding cassette transporter ABCG2. Biochem Pharmacol. 2016;104:139–147.
   PubMed Web of Science ®Google Scholar
• Saito J, Hirota T, Furuta S, . Association between DNA methylation in the miR-328 5’-Flanking region and inter-individual differences in miR-328 and BCRP expression in human placenta. PLoS ONE. 2013;8:e729061.
   Web of Science ®Google Scholar
• Wong AH, Gottesman II, Petronis A. Phenotypic differences in genetically identical organisms: the epigenetic perspective. Hum Mol Genet. 2005;14 Spec No 1:R11–R18.
   PubMed Web of Science ®Google Scholar
• Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA. 2008;105:10513–10518.
   PubMed Web of Science ®Google Scholar
• Gilad S, Meiri E, Yogev Y, et al. Serum microRNAs are promising novel biomarkers. PLoS ONE. 2008;3:e3148.
   PubMed Web of Science ®Google Scholar
• Van Balkom BW, Eisele AS, Pegtel DM, et al. Quantitative and qualitative analysis of small RNAs in human endothelial cells and exosomes provides insights into localized RNA processing, degradation and sorting. J Extracell Vesicles. 2015;4:26760.
   PubMed Web of Science ®Google Scholar
• Breuninger S, Erl J, Knape C, et al. Quantitative analysis of liposomal heat shock protein 70 (Hsp70) in the blood of tumor patients using a novel LipHsp70 ELISA. J Clin Cell Immunol. 2014;5:264.
   Google Scholar
• Gotanda K, Hirota T, Saito J, et al. Circulating intestine-derived exosomal miR-328 in plasma, a possible biomarker for estimating BCRP function in the human intestines. Sci Rep. 2016;6:32299.
   PubMed Web of Science ®Google Scholar